Story
AbCellera Shares Surge 22% on Positive Phase 2 Menopause Drug Trial Data

AbCellera Biologics Inc. (NASDAQ:ABCL) shares surged by as much as 22% on Monday after the company reported positive top-line results from a Phase 2 clinical trial for ABCL635, an investigational treatment for moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.
Trial Meets Primary Endpoints
The company announced that the Phase 2 study successfully met its primary efficacy endpoints. After a single dose, ABCL635 demonstrated a statistically significant reduction in both the frequency and severity of hot flashes at week four compared to a placebo.
According to the results, the treatment led to a significant decrease in symptoms:
- Frequency: A placebo-adjusted reduction of 5.3 moderate-to-severe vasomotor events per day.
- Severity: A placebo-adjusted reduction of 1.1 points on a severity scale.
The trial also showed improvements in sleep and in patients' global impression of change, AbCellera reported.
AdStudy Details and Safety Profile
The randomized, double-blind, placebo-controlled trial involved 92 postmenopausal women who were experiencing approximately 10 moderate or severe hot flashes daily. Participants received either a single 600 mg subcutaneous dose of ABCL635 or a placebo.
AbCellera stated that ABCL635 was well-tolerated over the four-week treatment period. The company reported no serious or severe adverse events, and no participants discontinued the study due to adverse events. The most common side effects observed in the treatment group were headache, fatigue, and injection site reactions.
Context for Investors
The positive data represents a key milestone for AbCellera, which is developing ABCL635 as a non-hormonal, long-acting, subcutaneous treatment. The drug targets the neurokinin 3 receptor. Following the announcement, the company held a conference call on Monday to discuss the trial results with investors and analysts.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.